Latest Healthpoint Biotherapeutics Stories
FORT WORTH, Texas, Feb. 1, 2013 /PRNewswire/ -- Healthpoint Biotherapeutics, a Smith & Nephew business (LSE: SN, NYSE: SNN), today announced the introduction of a Copay Assistance Program for patients who have been prescribed Collagenase SANTYL(®) Ointment and pay more than $50 out-of-pocket for their prescription. Under the program, eligible patients cover the first $50 and Healthpoint will pay up to the next $150 of out-of-pocket costs per prescription. The card can be used...
FORT WORTH, Texas, Nov. 28, 2012 /PRNewswire/ -- Smith & Nephew (LSE: SN, NYSE: SNN), the global medical technology business, announced today that it has signed an agreement to acquire substantially all of the assets of Healthpoint Biotherapeutics for $782 million in cash. The transaction is subject to regulatory approval and is expected to close in December 2012. Healthpoint Biotherapeutics, founded in 1992 by Chairman and CEO Paul Dorman, has been focused on biopharmaceutical...
FORT WORTH, Texas, Nov. 5, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the introduction of a 5 cm x 7 cm size of OASIS(®) Ultra Tri-Layer Matrix, a naturally-derived extracellular matrix (ECM) material formed from three layers of porcine small intestinal submucosa (SIS). The three-layer construct of ECM was designed to provide increased structure for difficult-to-heal and chronic wounds. "The triple-layer SIS technology in OASIS(®) Ultra has significantly...
FORT WORTH, Texas, Sept. 17, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced it has been named a 2012 Bronze STEVIE(®) Award Winner for the Video-Training category in The 10th Annual American Business Awards. The award was granted for the SENSES Program, a training DVD with accompanying poster, training card and recognition pins, developed to educate caregivers in the long-term care setting on how to recognize the signs of potential pressure ulcer development....
FORT WORTH, Texas, Sept. 11, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the initiation of a Phase III clinical trial investigating the efficacy of HP802-247 for the treatment of venous leg ulcers. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts. The study is designed to evaluate complete wound closure in subjects receiving HP802-247 plus compression therapy compared to those receiving vehicle control...
FORT WORTH, Texas, Aug. 13, 2012 /PRNewswire/ -- The Wound Institute today announced it has been named a 2012 Gold Award Winner in the 14(th) annual Web Health Awards((SM)) for its online Medical Education platform developed for healthcare professionals. Additionally, The Wound Institute Patient Portal, which provides educational resources designed for patients and caregivers, received a Merit Award. "We are honored to have been selected for these prestigious awards recognizing...
FORT WORTH, Texas, Aug. 2, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results for its Phase 2b clinical trial investigating the efficacy of HP802-247 in venous leg ulcers is published on The Lancet, beginning August 3, 2012, with Online First access to the article, followed by print publication in the next issue. HP802-247 is an investigational allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently under development for the...
FORT WORTH, Texas, July 25, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced that the results of a 24-week open-label follow-up to the HP802-247 Phase 2b trial will be presented by Robert Kirsner, MD, PhD, on Friday, July 27, 2012, from 3:55-4:15 pm, during the American College of Wound Healing and Tissue Repair held at the Swissotel in Chicago. HP802-247 is an allogeneic living cell bioformulation containing keratinocytes and fibroblasts currently being investigated...
FORT WORTH, Texas, June 20, 2012 /PRNewswire/ -- Healthpoint Biotherapeutics today announced the company is planning a significant upgrade to its 80,000 square foot research and manufacturing facility in Ft. Worth. The new, state-of-the-art facilities will comprise 25,000 square feet of manufacturing infrastructure, labs and clean room space for the production of cell-based therapies. "We are very pleased to be embarking on this important and innovative initiative at our...
FORT WORTH, Texas, June 11, 2012 /PRNewswire/ -- The Wound Institute today announced the launch of a new educational module "Guide to Chronic Wound Care," an accredited, online course designed to help primary care physicians, podiatrists, nurses, physical therapists, pharmacists and other healthcare professionals involved in treatment of patients with difficult to heal wounds. Healing problems can occur with any kind of wound, particularly in individuals who are gravely injured or...
